Peer Review History
Original SubmissionJune 14, 2019 |
---|
PONE-D-19-16947 Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC) PLOS ONE Dear Dr Altekruse, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please fully address the comments provided by the two reviewers. My main concerns are related to the methodological decisions that are not explained or clarified in the text. For example, what was the rationale/approach for variable selection in the adjusted analysis? There is no rationale provided for the base, base + one SES factor, or fully adjusted models. In addition there is no rationale for the parameterization of selected factors, nor the selection of reference categories, leading to some strange results with limited utility (i.e., 80+ for the reference group for age, etc.) Did you consider any effect modification analysis, for example to examine the relationship between covariates of interest (i.e., SES) and geographic region? Given the national data, there could be further exploration of the data and the relationships examined in the paper. Finally, there is limited information provided in the text regarding the measurement or meaning of the covariates included in the models. We would appreciate receiving your revised manuscript by Sep 15 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Becky L. Genberg Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This epidemiological study examines the relationship between multiple indicators of SES and fatal overdose in a nationally representative sample and fills an important gap in the overdose literature. The researchers present data drawn from the American Community Survey, which has been linked to fatal overdose data from the National Death Index. While this is an important topic with implications for targeted overdose prevention and response programs, grounding the research in the large body of existing literature on fatal overdose would strengthen the paper. There are also several methodological issues as well as questions around generalizability that need to be addressed. With minor revisions, this paper could be a timely contribution to the overdose literature. Abstract The results section of the abstract should be revised; there appears to be incomplete reporting e.g., urban group had higher risk than the rural group but was not reported, “HRs near two” etc and the wording is convoluted at times. The abstract refers to “final models” when the results only report one final model. I suggest rewriting the results section of the abstract to be more concise and more informative. Introduction Page 3: Nationwide, fatal opioid overdoses have disproportionately [2] but not exclusively [3] affected men, and particularly adolescent, young and middle-aged adult white men. -Clarify whether this is referring to fatal opioid overdose prevalence or rates over time and the historical period of relevance. It would be worth mentioning the reason why overdose has been conceptualized as a death of despair to strengthen the rationale for focusing on SES, and to cite the original paper that developed the theory. The cited reference does not use the phrase and so the intended connection is unclear. Given that this is a national study, more could be provided in the introduction about the relationship between overdose rates and geography to better contextualize the findings (e.g., urban vs. rural settings), including whether overdoses or low SES are known to be concentrated in certain locales. Much has been written about the current opioid epidemic. A description of the established risk factors of fatal overdose or at minimum including citations of published reviews (e.g., Dasgupta et al., AJPH; Martins et al., AJPH) would nicely set up the subsequent sections and lay the foundation for the known confounders (measured and unmeasured) that should be considered. Methods: Page 4: (12.8%) ACS respondents who were missing information necessary to meet the NCHS minimum criteria required for matching – did the authors conduct secondary analyses to understand the degree of bias due to this missingness e.g., if this group differed on socio-demographics? Page 5: The Census Bureau definition of rural [14] excluded metropolitan and micropolitan areas, incorporated census-designated places with populations of 2500 or more. All residential locations were classified as rural or urban. – This needs to be unpacked; it is an important factor with implications for targeting resources. It appears that rural vs. non-rural would be a more accurate description based on the current text. Could the authors instead use a more granular classification scheme? Page 6: Analyses that accounted for multistage sampling in the ACS were conducted using the PHREG procedure – clarify the number of levels included in the final model. Did this method account for correlations between individuals surveyed from the same area of residence (e.g., census division)? Page 6: incarceration at time of survey – clarify here and in the table whether this is referring to the setting in which the survey was conducted or if the individual had a history of incarceration. Page 6: Were any confounders considered for inclusion in the regression analysis? Access to naloxone is an example. If not, this should be stated in the limitations. Results: Page 8: Many variables as modeled contain extremely small cell sizes (e.g., n=36 among ages 80+; n=29 among Asian Pacific Islanders; n=43 American Indian Alaskan Native etc), which calls into question the validity of these results. Where appropriate, I would suggest re-categorization/collapsing those categories into another category to generate larger cell sizes and/or replacing reference groups containing small cells with new reference groups with larger samples; this will affect the precision of the Cox regression models. Table 2: Clarify whether the presented data are from the Final adjusted model or the Partially adjusted model Discussion Page 22: This nationally representative descriptive study – given that the paper includes data analysis, it is observational rather than descriptive. Page 22: Given that the term “opioid” is often used synonymously with prescription opioid, I suggest highlighting in the opening paragraph that the analysis also included deaths involving non-medical opioids including heroin and fentanyl. Page 22: What do the authors mean by “rehabilitate those at-risk for opioid overdose?” Replacing this with less stigmatizing language is recommended. Page 22: were any subpopulations undersampled? E.g., Asian Pacific Islanders; American Indian Alaskan Native Americans. How valid are the findings around race/ethnicity? Page 23: How does the poverty measure used account for regional differences in cost of living? Page 24: Compared to people who owned a house with a mortgage, renters or owners without a mortgage were at risk of fatal opioid overdose during the study period – what was the hypothesis? Was this a surprising finding? I would suggest explaining this finding further. Page 24: The availability and lethality of fentanyl – I suggest clarifying that it is mostly illicitly manufactured fentanyl. Page 24: Increased access to opioid agonist therapy for treating opioid use disorder may have merit, but currently adherence rates are low – it is unclear what is meant by “low” and what the possible underlying reasons may be. This statement does not add to the discussion and could be removed. Limitations: How stable are the SES indicators over time? It would be helpful if the authors could explain which SES variables are most susceptible to temporal change and which remain relatively stable over time. Limitations: Homelessness is highly prevalent among people who misuse opioids, and many of those who overdose are unstably housed. Same with individuals who are incarcerated at the time of the study. How does the ACS account for homeless and incarcerated individuals? If this is a limitation of the study, please state. Minor comments: typographic errors should be fixed throughout. Reviewer #2: Abstract: In the abstract, mentioning the American Community Survey (versus MDAC), is a bit confusing, since MDAC is mentioned in the title. I would suggest being consistent from the title to the abstract for those readers who are doing a brief read of your paper. Also, you could clarify that the SES attributes are based on the time of American Community Survey participation. Introduction The introduction to this paper is very brief and the first paragraph is a bit disjointed, briefly covering opioid overdose mortality (the focus of this paper), other deaths of despair (which I’m not sure is needed), and SES disparities. In the second paragraph, the authors circle back to state that there is existing research on demographic and geographic trends in opioid overdoses. The introduction may better justify the analysis if it is expanded. For example, the authors could structure the introduction to present the existing research on opioid overdose mortality and disparities, highlighting the lack of socioeconomic detail. In the second paragraph, they could introduce and expand the existing information on socioeconomic disparities in life expectancy that may be driven by opioid overdoses and other deaths of despair. They could also further explain some of the existing research on distressed communities to motivate looking more into SES indicators. Methods What are the NCHS minimum criteria for matching to the NDI you mention in line 84 (i.e. same as those in line 93-94)? Could you add these or provide a reference? Also, define NCHS at first mention in line 84 (later you spell it out without specifying that this is NCHS is lines 92-93) and it makes it seem like there are multiple criteria/procedures. This sentence needs clarification, I am not sure what you mean by ‘centered on one’: “Frequencies were estimated using weighted data adjusted to be centered on one, with rounding to four significant digits to protect against disclosure of individual information.” Results Table 1 has a footnote that says the cell frequencies are based on weighted data, but the frequencies add to the number that I understood to be the unweighted/sampled n ~3.9 million. The clarity of Table 2 might be improved by presenting the first column as the ‘Base Or Partially Adjusted Model’ – it is a bit confusing to only call that column the Base model and include HRs for SES covariates. The results section describing the HRs is quite long and needs proofreading. I would suggest condensing this section and only including the key findings to make sure they are not overlooked. For example, you begin the results section describing Table 2/regression models by saying “HRs for many age groups were higher in final than base models (Table 2).” I’m not sure the point of highlighting this since the interest is in the SES variables. Please also be consistent with how the HRs are presented in the results section – it is a bit distracting to see the results presented so many different ways (e.g. mix of HRs inside parentheses or just placed at end of the sentence). Discussion In general, I think the discussion needs more focus on the public health impact and potential actions/interventions from the results since you say in the abstract that these results are useful for overdose prevention targeting. I think there are also some opportunities to discuss harm reduction (e.g. naloxone co-prescribing in the context of pain treatment) that are not mentioned. The paragraph on health insurance is somewhat unclear - I’m not sure how the final two sentences connect to the results and the potential public health implications of this result aren’t clear. For example, should we increase insurance coverage and/or find ways to engage those without health insurance with harm reduction and addiction treatment services? One potential explanation for the higher overdose mortality among separated, divorced, or widowed people are that they may be more likely to use alone, conferring a higher fatal overdose risk. I’m a bit confused about how the first and second parts from this sentence are connected: “The availability and lethality of fentanyl has contributed to an emerging pattern of post-incarceration overdose deaths, with a median time from release to death of more than 90 days [40].” ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Ju Nyeong Park Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.
|
Revision 1 |
PONE-D-19-16947R1 Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC) PLOS ONE Dear Dr Altekruse, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. As you revise your manuscript according to the minor revisions suggested by the two reviewers, I also encourage you to give some additional thought to the relationship between race, SES and fatal overdose, and as reviewer #2 has suggested, consider presenting the partially adjusted results in light of the complex relationships between SES and race. We would appreciate receiving your revised manuscript by Jan 05 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Becky L. Genberg Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Major comments The manuscript has been greatly improved from the previous version. I have a couple of remaining comments. Abstract: Refrain from using stigmatizing language. Replace “disabled people” with “people with disabilities” Introduction: The authors have done a nice job of summarizing the literature on the opioid overdose epidemic. An explanation of the gaps and limitations in the literature would round out this section so that the reader can understand the novelty of the current study. Results: Given the large sample size, I suggest reporting one decimal place for all percentages, both in the text and the tables. In table 2, level of statistical significance would likely be of interest to readers. I would indicate using footnotes (e.g., * p <0.05, ** p<0.001 etc) Discussion: Another limitation is that medication and behavior therapy coverage was not measured. The authors may want to mention this fantastic consensus report that highlights national gaps in coverage https://www.nap.edu/catalog/25310/medications-for-opioid-use-disorder-save-lives Minor comments Abstract: Replace “individual” with “individual-level” in the second sentence of the abstract. In the results, “those with the highest level of educational attainment of high school” does this include college? This finding, as written, does not standalone. Reviewer #2: Thank you for the opportunity to review this revised manuscript. I have a few additional suggestions to improve the clarity and public health importance of the manuscript. 1. Throughout: use person-first language where you are able. For example, line 68: “the homeless, and recently released prisoners” could be changed to persons who have experienced homelessness, housing instability, or incarceration. Also line 285 “substance users” should be changed to persons who use substances 2. Line 24: “Opioid fatalities are a U.S. problem.” – I think the prior version’s topic sentence was stronger and you might remove this sentence in favor of expanding the second sentence’s justification for the analysis. 3. Line 29: Likewise “HRs for fatal opioid overdose by SES in final model:” in the results section is not needed. Clearer to go straight to the results you interpret. 4. Line 41: “West North Central state”, do you mean “West, North, or Central”? Potentially missing a word or were these areas combined? 5. Lines 45-46: Could strengthen the conclusions by suggesting how these findings from MDAC inform prevention, treatment, and rehabilitation (e.g. what communities or regions need more services?) 6. Introduction lines 69-71: “Some risk factors such as unemployment and health insurance status are optimally studied using individual-level longitudinal data, with adjustment for other covariates. [11]” I do not get a lot of information from this sentence about what is known about the relationship of employment and health insurance coverage with opioid overdose. Could you instead highlight the main finding(s) of citation 11? 7. Introduction, lines 77-78: “after multivariable adjustment” – It may be clearer to say you hypothesized these would remain independently associated with fatal opioid overdose even after adjustment for other socioeconomic and demographic indicators (or something similar). ‘Multivariable adjustment’ on its own leaves the reader unclear on what you are doing. 8. Methods, lines 93-95: “Representativeness of the sample relative to the United States population was enhanced by applying weights to account for variable sampling.” – I don’t think you need this sentence and it makes the description of sampling weights less clear. The phrase ‘variable sampling’ is vague – unclear if variable is used as an adjective (as in varying) or noun (as in age, sex, etc. variables used for sampling). 9. Results, line 156: “weighting to the U.S. population” could be clearer if you say “weighting to the age, sex, etc…distribution of the U.S. population.” Otherwise wording could imply that the sample size is weighted to the size of the US population and someone reading quickly or without much background in survey data analysis might misunderstand that only 3800 opioid overdoses occurred in the US if not clarified that the exact numbers do not represent the US population size. 10. The result in the final model that black participants were at lower risk of fatal overdose should be considered more thoroughly. The unadjusted and partially adjusted models suggest black race is a risk factor for fatal overdose and this association only becomes protective after adjusting for many SES related factors that disproportionately affect African American communities. A model considering race as a main exposure should not be adjusted for SES factors because race would predict some of those SES indicators but the SES factors would be mediators of relationships between race and opioid fatality (i.e., direction of causality is not SES factors predicting race which would be required for SES factors to confound relationship of race and overdose fatality). Thus the partial model may be more relevant here. I would suggest stating both the partial and full model results for race in your results and interpreting some of this in the discussion because it suggests that some attention to structural factors disproportionately affecting African Americans could decrease opioid overdose mortality among African Americans. Presenting only the full model results of a protective relationship suggests that African American communities are less affected by the opioid epidemic, which may not necessarily be the full story here. 11. Line 248: Might consider making the statement “patients using opioid therapy for chronic pain should be carefully selected” a bit more specific and actionable by citing CDC opioid prescribing guidelines (Dowell et al CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016). Could say something like: “physicians should weigh the benefits and risks of opioid therapy using national guidelines for opioid prescribing.” More recently these guidelines have been evaluated and you could also evaluate that literature in rewriting this sentence. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Ju Nyeong Park Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 2 |
Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC) PONE-D-19-16947R2 Dear Dr. Altekruse, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Becky L. Genberg Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
Formally Accepted |
PONE-D-19-16947R2 Socioeconomic risk factors for fatal opioid overdoses in the United States: Findings from the Mortality Disparities in American Communities Study (MDAC) Dear Dr. Altekruse: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Becky L. Genberg Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .